CSIR-IMTECH and Epygen Biotech, Mumbai, have entered into an agreement for the latter to develop PEGylated Streptokinase for treatment of Ischemic Stroke.
Epygen is the first company in India with exclusive license of this Novel Biological Entity (NBE) thrombolytic protein for ischemic stroke. Epygen Biotech Pvt Ltd is a biopharmaceutical company, engaged in research and manufacturing of Therapeutic Proteins for Oncology, Cardiovascular and Immune disorders.
PEGylated Streptokinase, the novel recombinant protein Thrombolytic molecule has been precisely engineered through decades of research for enhanced proteolytic stability and extended plasma half-life, fibrin-specificity and associated clot specificity, with reduced immuno-reactivity which would be significant attributes with unmistakable clinical advantages such as reduced probability of hemorrhage over current treatment regimens of thrombolytic drugs for acute stroke. These are huge advantages with a potential to transform the way ischemic stroke, deep-vein thrombosis, pulmonary embolism and acute myocardial infarction are treated around the globe, especially in the developing world.